You have 9 free searches left this month | for more free features.

CAR19

Showing 1 - 25 of 1,084

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Lymphoma Leukemia Trial in Minneapolis (allogeneic CAR19 regulatory T cells (CAR19-tTreg))

Not yet recruiting
  • Lymphoma Leukemia
  • allogeneic CAR19 regulatory T cells (CAR19-tTreg)
  • +2 more
  • Minneapolis, Minnesota
    Masonic Cancer Center - University of Minnesota
Dec 6, 2022

Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders Trial in Chapel Hill (iC9-CAR19 cells,

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • iC9-CAR19 cells
  • +3 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 21, 2022

Lymphoma, Lymphoma, B-Cell, Immune System Diseases Trial in Chapel Hill (iC9-CAR19 T cells, Bendamustine, Fludarabine)

Recruiting
  • Lymphoma
  • +4 more
  • iC9-CAR19 T cells
  • +4 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022

B Acute Lymphoblastic Leukemia Trial in London (PBLTT52CAR19)

Recruiting
  • B Acute Lymphoblastic Leukemia
  • London, United Kingdom
    Great Ormond Street Hospital
Dec 15, 2021

B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified Trial in Guangzhou, Guanzhou (CD19 CAR T-Cell(CAT19T2))

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-Cell Lymphoma, Unspecified
  • CD19 CAR T-Cell(CAT19T2)
  • Guangzhou, Guangdong, China
  • +1 more
Nov 4, 2022

People Living With HIV Treated With CD19-directed CAR T Cell

Active, not recruiting
  • Leukemia
  • +9 more
    • Philadelphia, Pennsylvania
      Pennsylvania Hospital
    Mar 29, 2023

    Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders Trial in Chapel Hill (iC9-CAR19 cells,

    No longer available
    • Acute Lymphoblastic Leukemia
    • +2 more
    • iC9-CAR19 cells
    • +3 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Dec 2, 2021

    Systemic Lupus Erythematosus Trial (CD19 CAR-T cell infusion)

    Not yet recruiting
    • Systemic Lupus Erythematosus
    • CD19 CAR-T cell infusion
    • (no location specified)
    Oct 24, 2023

    Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Metabolically Armed CD19 CAR-T cells
    • Hangzhou, Zhejiang, China
      The first affiliated hospital of medical college of zhejiang uni
    Nov 1, 2023

    Systemic Lupus Erythematosus Trial (CD19 Universal CAR-?d T Cells)

    Not yet recruiting
    • Systemic Lupus Erythematosus
    • CD19 Universal CAR-γδ T Cells
    • (no location specified)
    Oct 24, 2023

    B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

    Not yet recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • (no location specified)
    Oct 10, 2023

    Relapase and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells Trial in Beijing

    Recruiting
    • Relapase and Refractory B-cell Non-Hodgkin's Lymphoma
    • Decitabine-primed Tandem CD19/CD20 CAR T Cells
    • Decitabine-primed Tandem CAR19/20 engineered T cells
    • Beijing, Beijing, China
      Biotherapeutic Department of Chinese PLA General Hospital
    Mar 24, 2022

    CD19+ Malignancies: Relapse Post-allogeneic Transplant Trial in London (Infusion of modified CAR19 T-cells (4G7-CARD T-cells))

    Active, not recruiting
    • CD19+ Malignancies: Relapse Post-allogeneic Transplant
    • Infusion of modified CAR19 T-cells (4G7-CARD T-cells)
    • London, United Kingdom
      University College London Hospital
    Jun 16, 2021

    Relapsed and Refractory B-cell Lymphoma Trial (CD19 CAR-T and CD19 CAR-DC)

    Not yet recruiting
    • Relapsed and Refractory B-cell Lymphoma
    • CD19 CAR-T and CD19 CAR-DC
    • (no location specified)
    Oct 16, 2022

    Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Diffuse Large B Cell Lymphoma
    • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital
    Nov 19, 2023

    Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • +5 more
    • (no location specified)
    Aug 4, 2023

    SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

    Recruiting
    • SLE (Systemic Lupus)
    • +4 more
    • CD19 targeted CAR-T cells
    • Taiyuan, Shanxi, China
      Shanxi Bethune Hospital
    Sep 25, 2023

    B-cell Acute Lymphoblastic Leukemia Trial in Hefei (Metabolically Armed CD19 CAR-T cells)

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • Metabolically Armed CD19 CAR-T cells
    • Hefei, Anhui, China
      Anhui Provincial Hospital
    Feb 17, 2023

    Systemic Lupus Erythematosus (SLE) Trial in Shanghai (anti-CD19 CAR NK cells (KN5501))

    Recruiting
    • Systemic Lupus Erythematosus (SLE)
    • anti-CD19 CAR NK cells (KN5501)
    • Shanghai, China
      Changhai Hospital
    Aug 25, 2023

    Diffuse Large B-cell Lymphoma Trial in Hefei (Metabolically Armed CD19 CAR-T cells)

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Metabolically Armed CD19 CAR-T cells
    • Hefei, Anhui, China
      Anhui Provincial Hospital
    Feb 9, 2023

    CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Suzhou (ThisCART19A with Dose Level 1, ThisCART19A with Dose Level

    Recruiting
    • CAR
    • +2 more
    • ThisCART19A with Dose Level 1
    • ThisCART19A with Dose Level 2
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jan 18, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

    Recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
    • +4 more
    • Milwaukee, Wisconsin
      Medical College of Wisconsin
    Sep 22, 2022

    B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • B Lineage Lymphoblastic Lymphoma
    • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
    • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
    • Philadelphia, Pennsylvania
      Children's Hospital of Philadelphia
    Jan 25, 2023

    Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

    Not yet recruiting
    • Multiple Sclerosis
    • +2 more
    • KYV-101 anti-CD19 CAR-T cell therapy
    • Standard lymphodepletion regimen
    • Palo Alto, California
      Stanford Multiple Sclerosis Center
    Nov 13, 2023

    Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

    Recruiting
    • Lupus Nephritis
    • +2 more
    • KYV-101 anti-CD19 CAR-T cell therapy
    • Standard lymphodepletion regimen
    • Denver, Colorado
    • +1 more
    Jul 7, 2023